Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Breast Cancer Stage IV”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01594216
What this trial is testing

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

Who this might be right for
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine 25
Testing effectiveness (Phase 2)Study completedNCT00212095
What this trial is testing

Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer

Who this might be right for
Metastatic Breast Cancer
National University Hospital, Singapore 30
Testing effectiveness (Phase 2)Study completedNCT00664781
What this trial is testing

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Who this might be right for
brca1 Mutation Carrierbrca2 Mutation CarrierBreast Cancer+1 more
Cancer Research UK 78
Testing effectiveness (Phase 2)Study completedNCT00182767
What this trial is testing

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

Who this might be right for
Fallopian Tube CancerFemale Reproductive CancerRecurrent Breast Cancer+4 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Study completedNCT00072865
What this trial is testing

Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerNeoplasm Metastasis
Eli Lilly and Company 50
Testing effectiveness (Phase 2)Study completedNCT00371254
What this trial is testing

Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Who this might be right for
Breast CancerMetastasis
Bristol-Myers Squibb 55
Post-approval studies (Phase 4)Looking for participantsNCT07357597
What this trial is testing

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Who this might be right for
Stomatitis
AstraZeneca 100
Testing effectiveness (Phase 2)Study completedNCT01989780
What this trial is testing

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Japan Breast Cancer Research Group 160
Testing effectiveness (Phase 2)Study completedNCT00965523
What this trial is testing

Study of E7389 for Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Eisai Co., Ltd. 81
Testing effectiveness (Phase 2)Ended earlyNCT00101062
What this trial is testing

Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
University of Medicine and Dentistry of New Jersey
Large-scale testing (Phase 3)Active Not RecruitingNCT05654623
What this trial is testing

Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 624
Not applicableStudy completedNCT04176354
What this trial is testing

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Who this might be right for
Metastatic Breast Cancer
Pfizer 813
Testing effectiveness (Phase 2)Ended earlyNCT04659603
What this trial is testing

Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors

Who this might be right for
Breast Cancer MetastaticPancreatic Carcinoma Metastatic
Sanofi 50
Large-scale testing (Phase 3)Study completedNCT00078572
What this trial is testing

Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
GlaxoSmithKline 408
Testing effectiveness (Phase 2)Ended earlyNCT01528345
What this trial is testing

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 97
Not applicableStudy completedNCT04498481
What this trial is testing

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Who this might be right for
Breast Cancer
Pfizer 1
Not applicableStudy completedNCT03511781
What this trial is testing

Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer

Who this might be right for
Carcinoma Breast Stage IV
Tata Medical Center 30
Early research (Phase 1)Study completedNCT00005807
What this trial is testing

Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer

Who this might be right for
Breast CancerOvarian CancerUnspecified Adult Solid Tumor, Protocol Specific
Albert Einstein College of Medicine 40
Early research (Phase 1)Study completedNCT05567601
What this trial is testing

Doxil/Caelyx BE Study

Who this might be right for
Ovarian CancerAIDS-related Kaposi SarcomaMultiple Myeloma+1 more
Baxter Healthcare Corporation 36
Post-approval studies (Phase 4)Study completedNCT02447328
What this trial is testing

A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Locally Advanced orMetastatic Breast Cancer
AstraZeneca 83
Next Page